胃癌组织中IGF-1R及HER-2的表达及意义

目的探讨胃癌组织中HER-2及IGF-1R的表达及意义。方法免疫组化法检测80例胃癌组织中IGF-1R及HER-2的表达,同时分析二者的表达与胃癌患者的l临床病理特征的关系。结果HER-2与IGF-1R在胃癌中的表达分别为23．8％、83．8％;在正常胃黏膜组织中的阳性率分别为10．0％及20．0％,差异有统计学意义（P〈0．05）;二者表达与淋巴结转移及肿瘤浸润深度相关;另外IGF-1R的表达还与肿瘤分化程度相关。HER-2与IGF-1R在胃癌组织中的蛋白表达水平呈正相关（P=0．001,r=0．362）;二者均阳性表达的胃癌患者预后较差。结论IGF-1R及HER-2蛋白在胃癌中的表达与侵袭和转移相关,对预后判断有重要价值。     

瘦素及其功能性受体OB-Rb在非小细胞肺癌表达的临床病理研究

目的：研究瘦素和瘦素功能性受体OB-Rb在非小细胞肺癌（non-small cell lung cancer，NSCLC）中的表达，并探讨瘦素和OB-Rb在NSCLC发生、发展过程中的意义。方法：采用RT-PCR和免疫组织化学方法，检测38例NSCLC肿瘤组织及其癌旁组织中瘦素和瘦素受体OB-Rb的mRNA和蛋白表达情况，同时将其蛋白表达水平与NSCLC的临床病理参数进行相关性分析。结果：瘦素与OB-Rb的mRNA在肺癌组织表达水平显著高于癌旁组织（P=0．000）。瘦素蛋白在肺癌组织和癌旁组织的阳性表达率分别为71．1％和26．3％（P〈0．005），OB-Rb蛋白在肺癌组织和癌旁组织的阳性表达率分别为63．2％和31．6％（P〈0．010）；瘦素和OB-Rb蛋白与NSCLC细胞类型、分化程度、TNM分期及淋巴结转移无明显相关性（P〉0．05），瘦素与OB-Rb蛋白在NSCLC中的表达也无显著关联（P〉0．05）。结论：瘦素和OB-Rb在肺癌组织表达上调，瘦素可能是NSCLC发生、发展过程中的一种促肿瘤生长因子。瘦素和OB-Rb在NSCLC的促癌作用没有直接的协同效应，可能是通过各自不同的机制参与NSCLC的病程。     

瘦素和瘦素受体基因表达与乳腺癌发生发展的关系

目的探讨瘦素和瘦素受体基因表达与乳腺癌发生、发展及临床病理特征之间的关系。方法应用免疫组织化学方法检测132例原发性乳腺癌患者、66例乳腺良性病变患者及30例癌旁正常乳腺组织瘦素和瘦素受体基因的表达。结果瘦素及瘦素受体基因在乳腺癌组织中表达的阳性率分别为76．5％（101／132）和70．5％（92／132）,显著高于乳腺良性病组[56．1％（37／66）和56．1％（37／66）]、癌旁正常组织[46．7％（14／30）、43．3％（13／30）],差异有统计学意义（χ^2=8．72,P=0．003;χ^2=4．04,P=0．044;X。10．57,P=0．001;χ^2=7．94,P=0．005）;乳腺癌组织瘦素和瘦素受体基因的表达具有显著相关性（r=0．307,P〈0．05）;乳腺癌组织瘦素与瘦素受体基因的表达在不同年龄、绝经状态、肿瘤大小、分级、组织学类型、远处转移状况、雌激素受体和孕激素受体的表达状况方面差异均无统计学意义（P〉0．05）;但瘦素基因的表达在淋巴结转移患者中阳性率为91．7％,明显高于无淋巴结转移患者的67．9％,二者比较差异有统计学意义（χ^2=10．65,P=0．002）。结论瘦素和瘦素受体基因表达与乳腺癌的发生、发展有密切的关系,瘦素和瘦素受体可能是乳腺癌发生、发展的促进因子。     

瘦素 瘦素受体VEGF和CD34在结直肠癌中的表达

目的:探讨瘦素(Leptin)、瘦素受体(Oh-R)、血管内皮生长因子(VEGF)和CD34蛋白(标记组织微血管密度以反映血管形成活跃程度的特异性抗体)在结直肠癌中的表达及其生物学意义.方法:应用免疫组化SP法检测68例结直肠癌患者的结直肠癌组织、癌旁组织和正常结直肠组织中瘦素、瘦素受体、VEGF和CD34的表达情况,结合临床病理资料进行分析.结果:瘦素、瘦素受体和VEGF在结直肠癌组织中的阳性表达率明显高于癌旁组织和正常结直肠组织,其表达与肿瘤的病理学分级、肠壁浸润深度、淋巴结转移、Dukes分期、远处转移及有脉管瘤栓明显相关.微血管密度(MVD值)在结直肠癌组织中的表达明显高于癌旁组织和正常结直肠组织,癌旁组织高于正常组织.在结直肠癌组织中瘦素、瘦素受体、VEGF的表达与CD34表达具有一致性.结论:微血管密度是衡量结直肠癌发展、浸润及转移的重要指标.瘦素与瘦素受体结合促进结直肠癌细胞增殖.瘦素与VEGF协同作用可促进结直肠癌新生血管形成,促进结直肠癌的浸润和转移.     

胃癌组织EGFR和VEGF的表达及其意义

目的探讨胃癌组织EGFR和VEGF的表达及其与临床病理特征的关系。方法应用免疫组化方法检测正常胃黏膜和胃癌切除标本EGFR和VEGF的表达,并与临床病理参数进行比较分析。结果胃癌组织EGFR和VEGF阳性表达率分别为64.7%和58.8%;正常胃黏膜组织EGFR和VEGF阳性表达率分别为0%和10.0%,差异有统计学意义（P=0.000）;EGFR阳性表达与肿瘤分化程度、浸润深度、淋巴结转移、远处转移及临床TNM分期呈显著相关,VEGF阳性表达与肿瘤分化程度、浸润深度、淋巴结转移、远处转移、脉管内癌栓和临床TNM分期呈显著相关（P〈0.01和P〈0.05）。EGFR表达阳性者有69.7%同时伴有VEGF表达阳性,EGFR和VEGF双阳性表达者的根治切除率仅为30.4%,明显低于阴性表达者（P=0.000）。结论胃癌组织EGFR和VEGF表达上调与肿瘤分化程度、浸润深度、淋巴结转移、远处转移、脉管内癌栓和TNM分期有关,EGFR促进肿瘤血管生长可能通过上调VEGF表达,胃癌组织EGFR和VEGF表达可能成为从同期别病例中甄别靶向治疗获益病例的主要预后指标。     

胃癌组织HER-2表达预后意义分析

目的 探讨胃癌组织HER-2表达及其与患者预后的关系.方法 选取云南省肿瘤医院2009-02-01-2011-02-01手术切除的胃癌组织及相应的癌旁组织(距癌组织＞5 cm)77例,采用免疫组化法检测77例胃癌组织及其癌旁非肿瘤胃组织中HER-2的表达,分析HER-2表达与患者临床病理因素的关系,以及与预后的关系.结果 胃癌组织中HER-2的阳性表达率为10.4％(8/77),显著高于癌旁非肿瘤组织0(0/77),x2=8.438,P=0.003.HER-2表达与患者年龄(rs =0.353,P=0.002)、肿瘤分化程度(rs=-0.324,P=0.004)、淋巴结转移(rS=0.29,P=0.008)、Lauren分型(rs=-0.394,P＜0.001)及TNM分期(rs=0.331,P=0.003)有关,而与性别(rs=0.2,P=0.860)、民族(rs=-0.906,P=0.404)、肿瘤部位(rs=-0.019,P=0.871)、大小(rs=-0.060,P=0.606)及浸润深度(rs=0.107,P=0.354)无关.COX比例风险分析显示,肿瘤分化程度(HR=1.26,P=0.034)、TNM分期(HR=2.85,P=0.006)、有无淋巴结转移(HR-6.85,P=0.021)及肿瘤发生的年龄(HR =2.35,P＜0.001)是影响预后的独立危险因素,而HER-2的表达不是影响胃癌预后的独立危险因素(HR-1.02,P-0.071).生存分析显示,HER-2蛋白阳性表达的患者生存率与阴性表达者比较,差异无统计学意义,x2 =0.114,P=0.736.结论 胃癌组织中HER-2可呈阳性表达,检测HER-2表达对胃癌的临床治疗有一定指导意义,但它尚不能作为判断胃癌预后独立的指标.     

胃癌组织HER-2表达与临床病理因素相关性的探讨

目的:探讨HER-2在胃癌组织中的表达及其与临床病理特征和预后的关系.方法:用免疫组化法检测126例胃癌组织和30例正常胃黏膜组织中HER-2表达,并与病理参数及预后比较分析.结果:胃癌组织HER2表达阳性率为29.4%(37/126),正常胃黏膜组织中无HER-2表达,P<0.05;HER-2表达与病变部位、分化程度、年龄、肿瘤浸润深度、有无远处转移、有无淋巴结转移及预后等密切相关,P<0.05;而与性别、是否侵犯神经及是否侵犯脉管无关,P>0.05.结论:HER2表达与胃癌的生物学行为有一定的相关性,检测胃癌组织中HER2的表达对于胃癌的治疗及预后判断有一定指导意义.     

胃癌组织HER-3和Akt的表达及其临床意义

目的:检测胃癌组织与非肿瘤胃组织(胃黏膜及肌组织)中表皮生长因子受体-3(HER-3)、丝苏氨酸激酶(Akt)的表达及胃癌组织中HER-3、Akt的表达与临床病理参数及预后的关系.方法:免疫组化ElivisionTM二步法检测84例胃癌及15例非肿瘤胃组织中HER-3、Akt的表达,应用SPSS 13.0分析HER-3、Akt的表达与胃癌患者临床病理特征及预后的关系.结果:胃癌组织中HER-3阳性率为56.0%(47/84),过表达率为21.4%(18/84),Akt阳性率为48.3%(54/84),过表达率为31.0%(26/84).HER-3的阳性表达与临床分期、远处转移相关(P值分别为0.038和0.008),Akt的阳性表达与分化程度、淋巴结转移相关(P值分别为0.023和0.028),Akt的过表达与临床分期、肿瘤浸润深度、淋巴结转移相关,P值分别为0.014、0.009和0.034.HER-3阴性的总生存时间(OS)显著优于阳性者(P=0.023),Akt低表达的OS、无进展生存率(PFS)均显著优于高表达者,P＜0.001.结论:HER-3、Akt的表达与细胞的恶变相关.HER-3、Akt可能参与肿瘤细胞的粘附、增殖、浸润及转移的过程,可作为胃癌预后的预测因子.     

VEGF与MMP-2在胃腺癌组织中的表达及其与肿瘤侵袭转移的相关性研究

 目的　探讨血管内皮生长因子 (VEGF)和基质金属蛋白酶 2 (MMP 2 )在胃癌组织中的表达及其与胃癌侵袭转移的关系。方法　采用S P免疫组化染色法检测了VEGF和MMP 2在 80例胃癌原发灶和 4 0例淋巴结转移灶中的表达。结果　VEGF、MMP 2在胃癌原发灶组织中的阳性表达率分别为96 .2 5 %、86 .2 5 % ,在淋巴结转移灶中分别为 85 .0 0 %、70 .0 0 %。VEGF蛋白表达与肿瘤浸润深度、淋巴结转移关系密切 ,而与肿瘤分化程度无关 ;MMP 2与肿瘤分化、浸润深度、淋巴结转移均有关。结论　VEGF、MMP 2在肿瘤侵袭转移中起重要作用 ,可作为胃癌预后判断的指标。     

TFF3和VEGF表达与胃癌发生、浸润和转移的相关性

摘 要：［目的］ 探讨TFF3和VEGF的表达与胃癌发生、浸润和转移的相关性。［方法］ 采用免疫组织化学SP法检测70例胃癌组织及其癌旁组织、40名健康体检者的正常胃黏膜组织中TFF3和VEGF的表达情况。［结果］ TFF3 和VEGF在正常胃组织、癌旁组织和胃癌组织中的阳性表达率分别为5.0%、40.0%、58.6%和2.5%、47.1%、67.10%,同一指标组间比较差异均有统计学意义（P＜0.05）。TFF3在胃癌组织中的表达与局部淋巴结转移、TNM分期、预后有关,VEGF则与肿瘤分化程度、浆膜浸润程度、局部淋巴结转移、TNM分期、预后有关（P＜0.05）。TFF3和VEGF在胃癌中的表达呈正相关（r=0.532,P＜0.05）。［结论］ TFF3和VEGF的表达可能与胃癌的发生、浸润、转移和预后有关,两者在胃癌中的表达呈正相关,对胃癌的发生可能有协同作用。     

Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer

Background

Amplification and overexpression of human epidermal growth factor receptor-2 (HER-2) has been shown in subgroups of gastric cancer, correlated to more aggressive disease and predictive for the treatment with HER-2 antibodies. In this study, we examined the prognostic value of HER-2 expression in primary gastric cancer and in associated lymph node metastases and confirmed the role of HER-2 in tumor angiogenesis by examining vascular endothelial growth factor (VEGF) expression.

Methods

Immunohistochemistry was used to detect HER-2 and VEGF expression in 110 gastric cancer specimens and associated lymph node metastases and in 96 specimens of normal gastric mucosa.

Results

The expression level of HER-2 in gastric tissues was significantly higher than in normal tissues (19.1 % vs. 8.3 %; P < 0.05). HER-2 overexpression was homogeneous in primary gastric cancer and metastatic lymph nodes (P = 0.607). There was a significant positive correlation of HER-2 expression and VEGF expression (P = 0.007). HER-2 overexpression in primary tumor correlated with lymph node metastasis, distant metastasis, and American Joint Committee on Cancer (AJCC) stage. Cox regression multivariate analyses confirmed that tumor size, histological grade, lymph node ratio, AJCC stage, chemotherapy, and HER-2 expression were all prognostic factors. Patients with HER-2 positivity in both primary and metastatic tissues (+/+) had the poorest survival (OS, 12.5 months; DFS, 11.0 months) (P < 0.01).

Conclusions

HER-2 was significantly overexpressed in gastric cancer versus normal tissue and correlated with VEGF expression. HER-2 in tumor or lymph nodes was an independent negative prognostic factor.     

瘦素和瘦素功能性受体在非小细胞肺癌组织中的表达及其临床意义

目的　研究瘦素（ＯＢ）和瘦素功能性受体（ＯＢ-Ｒｂ）在非小细胞肺癌（ＮＳＣＬＣ）组织中的表达情况,探讨其表达水平与ＮＳＣＬＣ发生、发展及预后的关系。方法　采用免疫组化染色法检测１００例ＮＳＣＬＣ组织以及正常肺组织中ＯＢ和ＯＢ-Ｒｂ的表达,并研究其表达水平与临床病理参数之间的关系,运用单因素和多因素分析其与预后的关系。结果　ＯＢ在ＮＳＣＬＣ组织和正常肺组织的阳性表达率分别为７１％和２６％ （Ｐ＜０.０5）,ＯＢ-Ｒｂ则分别为６２％和３１％ （Ｐ＜０.０５）,ＨＥＲ-２在ＮＳＣＬＣ组织和正常肺组织的过度表达率分别为５４％和０（Ｐ＜０.０５）,三者在ＮＳＣＬＣ中的表达无明显相关性（Ｐ＞０.０５）。ＯＢ、ＯＢ-Ｒｂ和ＨＥＲ-２的表达与本组ＮＳＣＬＣ患者性别、年龄、吸烟史、病理类型均无关（Ｐ＞０.０５）;ＨＥＲ-２的表达与ＴＮＭ分期有相关性（Ｐ＜０.０５）;ＯＢ及ＨＥＲ-２的表达与淋巴转移有相关性（Ｐ＜０.０５）。单因素分析显示,ＮＳＣＬＣ患者性别、年龄、吸烟史和组织病理类型对预后无影响（Ｐ＞０.０５）,而ＴＮＭ分期、淋巴结转移、ＯＢ、ＯＢ-Ｒｂ和ＨＥＲ-２表达均对患者预后有显著影响（Ｐ＜０.０５）,ＯＢ、ＯＢ-Ｒｂ表达阳性以及ＨＥＲ-２过度表达的患者生存期明显缩短。Ｃｏｘ多因素分析显示,ＯＢ表达和淋巴结转移是影响ＮＳＣＬＣ患者预后的独立因子（Ｐ＝０.０００）。结论　ＯＢ、ＯＢ-Ｒｂ和ＨＥＲ-２在ＮＳＣＬＣ组织中高表达,ＯＢ、ＯＢ-Ｒｂ和ＨＥＲ-２表达高低可以作为区分组织良恶性的指标。ＯＢ、ＯＢ-Ｒｂ表达阳性以及ＨＥＲ-２过度表达的患者生存期明显缩短,ＯＢ表达情况可以作为判断ＮＳＣＬＣ患者预后的参考指标。     

血管内皮生长因子和抑癌基因p53在胃癌中的表达及其临床意义

目的 :研究血管内皮生长因子 (vascularendothelialgrowthfactor,VEGF)和抑癌基因p53表达的的相关性 ,与胃癌临床病理学指标的关系及其联合表达对胃癌患者预后的影响。方法 :应用免疫组化法同时检测 1 0 8例胃癌组织VEGF和P53蛋白表达水平。结果 :本组病例VEGF蛋白表达阳性率为 53 .7% ,P53蛋白表达阳性率为 57.4 % ,且两者呈正相关 (P <0 .0 1 )。VEGF蛋白表达水平与浆膜浸润、淋巴结转移和TNM分期有关 (P <0 .0 1 )。P53蛋白表达水平与患者年龄、肿瘤部位、脉管侵犯、浆膜浸润、淋巴结转移和TNM分期有关 (P <0 .0 5)。并且两者的表达和胃癌患者的预后呈负相关 (P <0 .0 1 )。结论 :VEGF和P53蛋白的表达呈正相关和胃癌的生物学特性有关 ,可作为估计胃癌预后的重要因素     

NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.

BACKGROUND: The full-length receptor p185HER-2 undergoes a metalloprotease-dependent cleavage producing a membrane-associated fragment (p95HER-2) in cultured breast cancer cells. P95HER-2 has potentially enhanced signaling activity, but its expression and role in human breast cancer is poorly characterized. PURPOSE: The purpose of this project was to characterize the expression of p95HER-2 in primary breast cancers and nodal metastasis, and to study association with clinicopathological factors. EXPERIMENTAL DESIGN: P95HER-2 and p185HER-2 were examined in 337 primary breast tumors and 81 metastatic lymph nodes by Western blot analysis, and tested for associations with other clinicopathological factors. RESULTS: P95HER-2 was present in 20.9% of primary tumors from node-negative patients, in 29.1% from patients with one to three metastatic nodes, and in 36.7% from patients with four or more metastatic nodes (P = 0.027). Whereas p185HER-2 overexpression was unrelated to nodal disease (P = 0.63), the odds of lymph node metastasis were enhanced 2.9-fold by the presence of p95HER-2 (48.8% of node-negative versus 73.5% of node-positive patients; P = 0.03; odds ratio = 2.9). P95HER-2 was more frequent in metastatic lymph nodes than in primary tumors (45.7% versus 26.7%; P = 0.0009), whereas p185HER-2 overexpression was similar in both (22.3% versus 23.5%; P = 0.933). P95HER-2 did not significantly correlate with patient age, tumor size, stage, histotype, or hormone receptor status. CONCLUSIONS: P95HER-2 in primary tumors was related to extent of lymph node involvement and was enhanced in nodal tissue suggesting an important role as a marker or cause in breast cancer metastasis. Examination of the prognostic value of p95HER-2 in breast cancer and its coexpression with metalloprotease activity seem warranted.     

Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression,and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma

Background: Anti-programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) immunotherapy has been proved to be effective on gastric cancer in ongoing clinical trials. However, the value of PD-L1 in predicting responses of patients with gastric cancer to anti-PD-1/PD-L1 immunotherapy is controversial. Some studies suggested that intra- and inter-tumoral heterogeneity of PD-L1 expression might explain the controversy. This study aimed to analyze the expression of PD-L1, PD-L2, and PD-1 as well as CD8(+) T-cell density in primary tumors and lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma to explore the heterogeneity of PD-1 signaling pathway molecules. Methods: In primary tumors and metastatic as well as non-metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma, we detected PD-L1 and PD-L2 expression with immunohistochemistry. CD8(+) T-cell density in primary tumors and PD-1 expression on CD8(+) T cells were detected with immunofluorescence. Uni-variate analysis was used to determine the prognostic values of them. Cox proportional hazard regression model was used to identify independent risk factors that affect patients' overall survival and disease-free survival. Results: Among 119 eligible patients who had undergone surgical resection, the positive rate of PD-L1 was higher in metastatic lymph nodes than in primary tumors (45.4％ vs. 38.7％,P= 0.005); the positive rate of PD-1 on CD8(+) T cells was significantly higher in primary tumors and metastatic lymph nodes than in tumor-free lymph nodes (both P < 0.001). The intensity of PD-1 expression on CD8(+) T cells in primary tumors and in metastatic lymph nodes were stronger than that in tumor-free lymph nodes from the same patient. Beside, the positive rate of PD-L2 did not show any differences between primary tumors and metastatic lymph nodes. In multivariate analysis, PD-L1 expression, PD-L2 expression, a low density of CD8(+) T cells in primary tumors, and PD-1 expression on CD8(+) T cells in primary tumors were associated with poor prognosis.Conclusion: The expression of PD-L1 is heterogeneous in primary tumors and in metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma, which might explain the inconsistent results in assessing the prognostic value of PD-L1 expression in previous studies.     

Prognostic role of p‐mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer

Despite the great interest in mammalian target of rapamycin (mTOR) as a potential anticancer therapy target, the prognostic role of mTOR in gastric cancer has not been elucidated. In this study, we investigated mTOR expression in gastric cancer tissues and in metastatic lymph nodes and examined its association with clinical outcome. A total of 290 patients with pT2b gastric cancer were enrolled in this study. Patients were divided into 3 groups according to metastatic lymph node status: Group 1 contained 96 patients without lymph node metastasis, Group 2 contained 102 patients with a few (1–2) metastatic lymph nodes and Group 3 contained 92 patients with extensive (>16) lymph node metastasis. Phosphorylated mTOR expression was determined immunohistochemically using tissue microarrays. p‐mTOR expression was observed in 36.5% of the gastric cancer tissues in Group 1, 39.2% in Group 2 and 60.9% in Group 3. A significant correlation was found between p‐mTOR expression in gastric cancer tissues and in metastatic lymph nodes. The Borrmann type in Group 1, perineural invasion and p‐mTOR expression in metastatic lymph nodes in Group 2 and p‐mTOR expression in metastatic lymph nodes in Group 3 were found to be independent prognostic factors of disease‐free survival. The 5‐year disease free survival rate of Group 2 patients was 84.4% in negative p‐mTOR and 66.1% in positive p‐mTOR expression in metastatic lymph nodes (p = 0.015). The 5‐year disease free survival rate of Group 3 patients was 37.3% in negative p‐mTOR and 14.9% in positive p‐mTOR expression in metastatic lymph nodes (p = 0.037). There was a linear correlation between the rate of tumor recurrence and mTOR expression scores in metastatic lymph nodes. In pT2b gastric cancer, p‐mTOR expression in gastric cancer is associated with the extent of lymph node metastasis, and p‐mTOR expression in metastatic lymph nodes is correlated with poor disease‐free survival. mTOR may harbor significant potential for a prognostic biomarker and therapeutic target for gastric cancer treatment.     

胃癌组织中Ets-1的表达及其与血管生成临床病理特征和预后的关系

目的 探讨胃癌组织、癌旁组织及淋巴结转移灶中Ets-1表达的临床意义,分析Ets-1表达与血管生成、临床病理特征及预后的关系.方法 应用免疫组化SP法,采用组织芯片技术,检测189例胃癌组织、54例癌旁组织、41例淋巴结转移灶及32例正常胃黏膜中Ets-1蛋白的表达.对胃癌患者通过上门或电话进行问卷随访.结果 胃癌组织、癌旁组织和正常胃黏膜Ets-1的阳性表达率分别为71.4%、29.6%和18.8%,3组间差异有统计学意义(P＜0.01).135例Ets-1表达阳性的胃癌组织微血管密度(MVD)为30.42±15.21,54例Ets-1表达阴性的胃癌组织MVD为25.73±11.50.两组差异有统计学意义(P=0.042).Ets-1蛋白表达与浸润深度、淋巴结转移有关(P＜0.01),与性别、年龄、肿瘤大小、分化程度、Lanren分型无关(P＞0.05).41例淋巴结转移灶和相对应的41例胃癌组织Ets-1表达阳性率分别为84.4%和58.5%,差异有统计学意义(P=0.007).单因素分析显示,Ets-1表达对胃癌患者生存期的影响有统计学意义(P＜0.05),Cox多元回归分析显示,Ets-1表达不是胃癌患者预后的独立影响因素(P＞0.05).结论 Ets-1在促进胃癌血管生成中发挥着重要作用,在胃癌的发生、发展中扮演了重要角色,Ets-1表达对胃癌患者的生存期有一定影响,胃癌淋巴结转移灶和原发灶肿瘤组织中Ets-1的表达不同,具有异质性.     

PDGF-D及其受体在胃癌组织中的表达及意义

目的探讨血小板衍生生长因子-D（PDGF-D）及其受体PDGFRβmRNA在胃癌组织中的表达及其与临床病理特征的关系。方法用RT-PCR方法检测58例胃癌及相对应的癌旁标本中PDGF-D及PDGFRβ mRNA的表达,分析其与临床病理特征的关系。结果PDGF-D及PDGFRβ在胃癌组织中的阳性表达率（98.28%,72.41%）均高于癌旁组织（87.93%,53.45%）,P均＜0.05。PDGFRβ与PDGF-D的表达呈正相关（r=0.40,P＜0.05）。PDGF-D mRNA的表达水平与胃癌的淋巴结及远处转移和复发有关（P＜0.05）,与其他临床病理特征无关（P＞0.05）。结论PDGF-D在胃癌的发生、发展和转移、复发中可能起着重要的作用,可作为预测胃癌转移和复发的有意义指标。     

VEGF-C和VEGF-D在胃癌及相关淋巴结组织中表达和临床意义的研究

目的：比较血管内皮生长因子C（vascular endothelial growth factor C,VEGF-C）和血管内皮生长因子D（vascular endothelial growth factor D,VEGF-D）在胃癌和相关淋巴结的表达,并评价其预后意义.方法：采用原位杂交技术检测45例胃癌患者原发病灶和转移淋巴结中VEGF-C和VEGF-D mRNA的表达水平;并检测转移及非转移淋巴结中VEGF-C和VEGF-D mRNA表达差异.结果：71%和62.2%的胃癌原发病灶可见VEGF-C和VEGF-D mRNA表达,原发病灶阳性者,相应的淋巴结转移病灶都可见VEGF-C和VEGF-D mRNA表达,55.6%和51.1%的胃癌患者淋巴结转移病灶VEGF-C和VEGF-D mRNA表达水平高于原发病灶,原发病灶和转移病灶淋巴管生成表达水平的差异与胃癌的预后密切相关（P＜0.05）.结论：胃癌癌细胞转移至淋巴结后淋巴管生成因子表达可能进一步提高,以进一步增强转移能力.